TIMI 15B evaluated the pharmacodynamic response, safety and pharmacokinetics of the GP IIb/IIIa inhibitor RPR 109891 given intravenously followed by oral administration for the treatment of patients with acute coronary syndromes. MAIN RESULTS: First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the … Continue reading TIMI 15B